Can Fite Biopharma (STU:CF5) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CF5 Can Fite Biopharma Ltd STU:CF5
53 GF Score
Price €101.00
GF Value €194.21
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Can Fite Biopharma Quality Rank Related Terms

STU:CF5
53GF Score
Can Fite Biopharma Ltd STU:CF5
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Can Fite Biopharma (STU:CF5) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of €101.00 is trading 48% below its estimated GF Value™ of €194.21.

Key valuation signals for STU:CF5:

  • Quality Rank:
  • GF Value™: €194.21 vs. price of €101.00 (48% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the STU:CF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Can Fite Biopharma Business Description

Other Exchanges CANF:USACANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
53GF Score

Get the complete analysis for STU:CF5

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€101.00
Price
€194.21
GF Value